Outcomes and Treatment Approaches for Super-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Importance: Super-refractory status epilepticus (SRSE) is defined as status epilepticus (SE) that continues or recurs 24 hours or more after the onset of anesthetic therapy or recurs on the reduction/withdrawal of anesthesia. Current clinical knowledge of the disease and optimal treatment approach is sparse. Objective: To systematically assess clinical characteristics, causes, outcomes, prognostic factors, and treatment approaches for patients with SRSE. Design, Setting, and Participants: In this systematic review and meta-analysis, all studies reporting adult patients (18 years or older) diagnosed with nonanoxic SRSE were considered for inclusion, irrespective of study design. The databases used were MEDLINE, Cochrane Library, EMBASE, and ClinicalTrials.org (database inception through May 5, 2022). Data extraction and synthesis: The study complied with the PRISMA guidelines for reporting, data extraction, and data synthesis. Different tools were used to assess risk of bias. All available data were extracted and missing data were neither imputed nor completed by contacting the study authors. Main outcome and measures: Successful treatment of SRSE, in-hospital mortality, and disability at discharge (estimated modified Rankin Scale). Results: The study team identified a total of 95 articles and 30 conference abstracts reporting 1200 patients with nonanoxic SRSE (266 individual patients were available for meta-analysis). They had a mean SRSE duration of 36.3 days, mean age of 40.8 years, and equal sex distribution. Patients with SRSE had a distinct pattern of etiologies where acute cerebral events and unknown etiologies accounted for 41.6% and 22.3% of all etiologies, respectively. Reports of SRSE caused by, eg, alcohol, drugs, or tumors were rare. At discharge, only 26.8% had none to slight disability (none, 16 [8.4%]; nonsignificant and slight disability, 35 [18.4%]). In-hospital mortality was 24.1%. Mortality stabilized after long-term treatment (more than 28 days) but with increased rates of seizure cessation and moderate to severe disability. Established prognostic factors, such as age and etiology, were not associated with in-hospital mortality. Reported treatment with ketamine, phenobarbital, other barbiturates, vagus nerve stimulator, and ketogenic diet were not associated with outcome. Conclusion and Relevance: Patients with SRSE are distinct due to their pattern of care (eg, long-term treatment to younger patients without negative prognostic factors and unknown/nonmalignant etiologies) and their natural course of SE. Very long-term treatment was associated with lower mortality and high odds of cessation of SRSE but increased risk of moderate to severe disability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“multimodal neuromonitoring has no large RCTs”
From Hallucination Rate of Peer-Reviewed Citations Generated by Large Language Models in Neurocritical Care (2026) · cites this paper as [19]
In the citing paper
“SRSE is less published, and large prospective trials are lacking”
From Hallucination Rate of Peer-Reviewed Citations Generated by Large Language Models in Neurocritical Care (2026) · cites this paper as [19]
In the citing paper
“SRSE is less published, and large prospective trials are lacking”
From Hallucination Rate of Peer-Reviewed Citations Generated by Large Language Models in Neurocritical Care (2026) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
The REDCap consortium: building an international community of software platform partners
Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G., Delacqua, F., Kirby, J., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103208 · Cited by 24,013
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., Lagae, L., Moshé, S. L., Peltola, J., Roulet Perez, E., et al. (2017) · Epilepsia · doi:10.1111/epi.13670 · Cited by 3,483
Methodological quality and synthesis of case series and case reports
Murad, M. H., Sultan, S., Haffar, S., & Bazerbachi, F. (2018) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2017-110853 · Cited by 2,242
Research works printed but not linked: 46
- Shorvon, 2011, The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol., Brain, 134, 2802, 10.1093/brain/awr215 · DOI · Paper page
- Trinka, 2022, Management of status epilepticus, refractory status epilepticus, and super-refractory status epilepticus., Continuum (Minneap Minn), 28, 559, 10.1212/CON.0000000000001103 · DOI
- Delaj, 2017, Refractory and super-refractory status epilepticus in adults: a 9-year cohort study., Acta Neurol Scand, 135, 92, 10.1111/ane.12605 · DOI
- Kantanen, 2017, Long-term outcome of refractory status epilepticus in adults: a retrospective population-based study., Epilepsy Res, 133, 13, 10.1016/j.eplepsyres.2017.03.009 · DOI
- Strzelczyk, 2017, Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany., Epilepsia, 58, 1533, 10.1111/epi.2017.58.issue-9 · doi:10.1111/epi.2017.58.issue-9
- Kantanen, 2017, Predictors of hospital and one-year mortality in intensive care patients with refractory status epilepticus: a population-based study., Crit Care, 21, 71, 10.1186/s13054-017-1661-x · DOI
- Shorvon, 2013, The London-Innsbruck Status Epilepticus Colloquia 2007-2011, and the main advances in the topic of status epilepticus over this period., Epilepsia, 54, 11, 10.1111/epi.2013.54.issue-s6 · doi:10.1111/epi.2013.54.issue-s6
- Dutta, 2022, Medium-chain triglyceride ketogenic diet as a treatment strategy for adult super-refractory status epilepticus., Indian J Crit Care Med, 26, 139, 10.5005/jp-journals-10071-24073 · doi:10.5005/jp-journals-10071-24073
- Newey, 2019, Super-refractory status epilepticus treated with high dose perampanel: case series and review of the literature., Case Rep Crit Care, 2019, 10.1155/2019/3218231 · DOI
- Rossetti, 2008, Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy., J Neurol, 255, 1561, 10.1007/s00415-008-0989-1 · doi:10.1007/s00415-008-0989-1
- 1993, Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy., Epilepsia, 34, 592, 10.1111/epi.1993.34.issue-4 · doi:10.1111/epi.1993.34.issue-4
- Beghi, 2010, Recommendation for a definition of acute symptomatic seizure., Epilepsia, 51, 671, 10.1111/epi.2010.51.issue-4 · doi:10.1111/epi.2010.51.issue-4
- Riley, 2017, CARE guidelines for case reports: explanation and elaboration document., J Clin Epidemiol, 89, 218, 10.1016/j.jclinepi.2017.04.026 · DOI · Paper page
- Caranzano, 2022, Ketamine in adult super-refractory status epilepticus: efficacy analysis on a prospective registry., Acta Neurol Scand, 145, 737, 10.1111/ane.v145.6 · doi:10.1111/ane.v145.6
- Strzelczyk, 2019, Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain., Acta Neurol Scand, 139, 369, 10.1111/ane.13061 · DOI
- Tian, 2015, Super-refractory status epilepticus in West China., Acta Neurol Scand, 132, 1, 10.1111/ane.2015.132.issue-1 · doi:10.1111/ane.2015.132.issue-1
- Uchida, 2018, Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity., Acta Neurol Scand, 137, 432, 10.1111/ane.2018.137.issue-4 · doi:10.1111/ane.2018.137.issue-4
- Thakur, 2014, Ketogenic diet for adults in super-refractory status epilepticus., Neurology, 82, 665, 10.1212/WNL.0000000000000151 · DOI · Paper page
- Anand, 2021, Ketogenic diet for super-refractory status epilepticus: a case series and review of literature., Ann Indian Acad Neurol, 24, 111, 10.4103/aian.AIAN_170_20 · doi:10.4103/aian.aian_170_20
- Rosenthal, 2017, Brexanolone as adjunctive therapy in super-refractory status epilepticus., Ann Neurol, 82, 342, 10.1002/ana.v82.3 · doi:10.1002/ana.v82.3
- Höfler, 2016, (S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study., CNS Drugs, 30, 869, 10.1007/s40263-016-0371-2 · DOI
- Pugin, 2014, Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study., Crit Care, 18, R103, 10.1186/cc13883 · doi:10.1186/cc13883
- Jose, 2021, Predictors of outcome in super refractory status epilepticus., Epilepsy Behav, 118, 10.1016/j.yebeh.2021.107929 · DOI
- Kantanen, 2015, Incidence and mortality of super-refractory status epilepticus in adults., Epilepsy Behav, 49, 131, 10.1016/j.yebeh.2015.04.065 · doi:10.1016/j.yebeh.2015.04.065
- Sabharwal, 2020, Secondary hypothermia in patients with super-refractory status epilepticus managed with propofol and ketamine., Epilepsy Behav, 105, 10.1016/j.yebeh.2020.106960 · doi:10.1016/j.yebeh.2020.106960
- Byun, 2015, Mega-dose phenobarbital therapy for super-refractory status epilepticus., Epileptic Disord, 17, 444, 10.1684/epd2.2015.17.issue-4 · doi:10.1684/epd2.2015.17.issue-4
- Koh, 2021, Pentobarbital coma therapy for super-refractory status epilepticus and in-hospital mortality: an observational study., Epileptic Disord, 23, 833, 10.1684/epd2.v23.6 · doi:10.1684/epd2.v23.6
- Lin, 2019, The different clinical features between autoimmune and infectious status epilepticus., Front Neurol, 10, 25, 10.3389/fneur.2019.00025 · DOI
- Misra, 2017, A study of super refractory status epilepticus from India., Front Neurol, 8, 636, 10.3389/fneur.2017.00636 · DOI
- Hocker, 2016, Progressive brain atrophy in super-refractory status epilepticus., JAMA Neurol, 73, 1201, 10.1001/jamaneurol.2016.1572 · doi:10.1001/jamaneurol.2016.1572
- Kaul, 2022, Modified low ratio ketogenic therapy in the treatment of adults with super-refractory status epilepticus., JPEN J Parenter Enteral Nutr, 46, 1819, 10.1002/jpen.v46.8 · doi:10.1002/jpen.v46.8
- Alkhachroum, 2021, Quantitative EEG-based seizure estimation in super-refractory status epilepticus., Neurocrit Care, 36, 897, 10.1007/s12028-021-01395-x · DOI
- Gugger, 2020, New-onset refractory status epilepticus: a retrospective cohort study., Seizure, 74, 41, 10.1016/j.seizure.2019.12.002 · DOI
- Kerin, 2021, A retrospective cohort study of super-refractory status epilepticus in a tertiary neuro-ICU setting., Seizure, 85, 90, 10.1016/j.seizure.2020.12.020 · doi:10.1016/j.seizure.2020.12.020
- Madžar, 2017, Factors associated with occurrence and outcome of super-refractory status epilepticus., Seizure, 52, 53, 10.1016/j.seizure.2017.09.003 · DOI
- Dubey, 2017, Spectrum and predictors of refractory status epilepticus in a developing country., Can J Neurol Sci, 44, 538, 10.1017/cjn.2017.28 · DOI
- Chateauneuf, 2017, Super-refractory status epilepticus: epidemiology, early predictors, and outcomes., Intensive Care Med, 43, 1532, 10.1007/s00134-017-4837-6 · doi:10.1007/s00134-017-4837-6
- Roberg, 2022, Prediction of long-term survival after status epilepticus using the ACD score., JAMA Neurol, 79, 604, 10.1001/jamaneurol.2022.0609 · DOI
- Kortland, 2016, Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany., Epilepsia, 57, 2056, 10.1111/epi.2016.57.issue-12 · doi:10.1111/epi.2016.57.issue-12
- Leitinger, 2019, Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes., Epilepsia, 60, 53, 10.1111/epi.2019.60.issue-1 · doi:10.1111/epi.2019.60.issue-1
- Rodin, 2019, High long-term mortality after incident status epilepticus in adults: results from a population-based study., Epilepsia, 60, 33, 10.1111/epi.2019.60.issue-1 · doi:10.1111/epi.2019.60.issue-1
- Novy, 2010, Refractory status epilepticus: a prospective observational study., Epilepsia, 51, 251, 10.1111/epi.2010.51.issue-2 · doi:10.1111/epi.2010.51.issue-2
- Leitinger, 2015, Epidemiology-based mortality score in status epilepticus (EMSE)., Neurocrit Care, 22, 273, 10.1007/s12028-014-0080-y · DOI · Paper page
- Kapur, 2019, Randomized trial of three anticonvulsant medications for status epilepticus., N Engl J Med, 381, 2103, 10.1056/NEJMoa1905795 · DOI · Paper page
- Brigo, 2019, Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis., Epilepsy Behav, 10.1016/j.yebeh.2019.106466 · DOI
- Legriel, 2016, Hypothermia for neuroprotection in convulsive status epilepticus., N Engl J Med, 375, 2457, 10.1056/NEJMoa1608193 · DOI · Paper page
Cited by
Seifi, A., & Seyfi, A. (2026) · Critical Care Explorations · doi:10.1097/cce.0000000000001474 · Cited by 1
Metadata
- Authors
- Cornwall, C. D., Krøigård, T., Kristensen, J. S. S., Callesen, H. E., & Beier, C. P.
- Affiliations
- Department of Neurology, Odense University Hospital, Odense, Denmark
- Metodekonsulent Callesen, Silkeborg, Denmark
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2023-09-01
- Volume
- 80
- Issue
- 9
- Pages
- 959
- ISSN
- 2168-6149
- Cited by
- 55
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes and Treatment Approaches for Super-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1001/jamaneurol.2023.2407
- The paper
- Cornwall, C. D., Krøigård, T., Kristensen, J. S. S., Callesen, H. E., & Beier, C. P. (2023). Outcomes and Treatment Approaches for Super-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2023.2407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.